Company
Averna Therapeutics
Delivering What’s Next in Genetic Medicine
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Averna Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Averna Therapeutics is developing technology to safely and effectively deliver and durably integrate large sets of genetic instructions, something that viral approaches have struggled to do. Averna’s approach is based on RNA instructions that convert to stable DNA, delivered by lipid nanoparticles (LNPs).
Funding snapshot
- Total raised
- $85MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $85M2024-04-08
Funding rounds
- Round, 2024
- $85M2024-04-08, SEC form D sold, 13 investors
Loading relationship preview